News & Articles

Much-needed diagnostics supplies will help accelerate testing capabilities of hospitals and clinics across India

The new Access AMH Advanced aims to provide validated cut-offs for the assessment of ovarian reserve and ovarian response as an aid for women undergoing in vitro fertilization (IVF)

Watch world-leading clinical scientists and healthcare professionals online, June 22-23, to discover the latest tools and techniques advancing COVID-19 diagnostic testing, cardiovascular treatments, point-of-care and more

Collaboration follows successful acquisition and commercialization of Oxsed, an Oxford University Spin-out, to scale OxLAMP rapid COVID-19 test globally

A new study shows that the less-invasive saliva test for COVID-19 gives just as accurate results as those of the nasopharyngeal specimen.

The fast time-to-result includes a pretreatment process to inactivate the virus as a safeguard for laboratory staff handling the samples

New findings pave way to potentially improved assessment of measurable residual disease in AML patients

New service reduces project time from months to weeks for biopharma customers

The Allplex SARS-CoV-2 Master Assay can detect a total of 10 targets including four coronavirus genes

Seegene’s new product filters COVID-19 and variants during primary PCR testing in 1 hr 55 min

Dr. Boye Schnack Nielsen shares tips for running successful in situ hybridization assays as he provides insights on how RNA detection methods have evolved over time

The antigen test is used to detect the nucleocapsid protein antigen in SARS-CoV-2

Seegene can produce 300,000 variant diagnostic test kits, capable of testing 30 million people every month

Highly complementary cell counting and analysis capabilities bolster preclinical portfolio and enhance QA/QC capabilities in cell and gene therapy and biologics manufacturing

The Simplexa™ SARS-CoV-2 Variants Direct assay aims to enable detection of four mutations associated with virus variants without requiring upfront RNA extraction

The availability of an International Standard (IS) for antibodies facilitates the standardization of SARS-CoV-2 serological methods

Platform poised to be first CLIA-waived CRISPR-based, point-of-care COVID-19 device with central-lab performance, developed in collaboration with Sherlock Biosciences

For a chance to win a $500/£400/450€ Amazon Gift Card, cast your vote for the new products which have made the most difference to clinical diagnostics

In a Phase 3 trial, the vaccine was 100% effective and generally well tolerated in participants aged 12 to 15 years

Discover how collaborative research between big pharma and academia is using the latest proteomics platforms to revolutionize drug discovery